1/30
08:03 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Bank of America Corporation from $246.00 to $260.00. They now have a "buy" rating on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Bank of America Corporation from $246.00 to $260.00. They now have a "buy" rating on the stock.
1/30
02:18 am
asnd
RBC Maintains Outperform Rating on Ascendis Pharma (ASND) Amid Growth Targets [Yahoo! Finance]
Low
Report
RBC Maintains Outperform Rating on Ascendis Pharma (ASND) Amid Growth Targets [Yahoo! Finance]
1/29
07:41 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
1/27
06:00 pm
asnd
Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Medium
Report
Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
1/25
11:28 pm
asnd
Ascendis: Why I'm Skeptical On Takeover Rumors, Long-Term Targets [Seeking Alpha]
Low
Report
Ascendis: Why I'm Skeptical On Takeover Rumors, Long-Term Targets [Seeking Alpha]
1/25
10:40 pm
asnd
Ascendis: Why I'm Sceptical On Takeover Rumours, Long-Term Targets [Seeking Alpha]
Low
Report
Ascendis: Why I'm Sceptical On Takeover Rumours, Long-Term Targets [Seeking Alpha]
1/25
03:34 am
asnd
Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After Strong Recent Share Price Momentum [Yahoo! Finance]
Low
Report
Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After Strong Recent Share Price Momentum [Yahoo! Finance]
1/23
05:06 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/20
08:41 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) was given a new $330.00 price target on by analysts at Wells Fargo & Company.
Medium
Report
Ascendis Pharma A/S (NASDAQ:ASND) was given a new $330.00 price target on by analysts at Wells Fargo & Company.
1/20
08:11 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Medium
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
1/12
06:37 pm
asnd
What Ascendis Pharma (ASND)'s Phase 2 COACH Combo Data Means For Shareholders [Yahoo! Finance]
Medium
Report
What Ascendis Pharma (ASND)'s Phase 2 COACH Combo Data Means For Shareholders [Yahoo! Finance]
1/10
01:06 am
asnd
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/9
06:01 pm
asnd
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
1/9
07:18 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Medium
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
1/8
04:56 pm
asnd
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) [Yahoo! Finance]
Medium
Report
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) [Yahoo! Finance]
1/8
04:01 pm
asnd
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
Low
Report
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
1/7
03:02 pm
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its "buy" rating reaffirmed by analysts at Cowen Inc.
1/7
10:58 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its "buy" rating reaffirmed by analysts at TD Cowen. They now have a $325.00 price target on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its "buy" rating reaffirmed by analysts at TD Cowen. They now have a $325.00 price target on the stock.
1/5
09:15 am
asnd
Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/5
08:30 am
asnd
Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference
12/21
02:13 pm
asnd
Assessing Ascendis Pharma's 2025 Valuation After Big Run and DCF Upside Potential [Yahoo! Finance]
Medium
Report
Assessing Ascendis Pharma's 2025 Valuation After Big Run and DCF Upside Potential [Yahoo! Finance]
12/15
03:25 am
asnd
Here's My Prediction For Who Could Acquire Ascendis Pharma [Seeking Alpha]
Medium
Report
Here's My Prediction For Who Could Acquire Ascendis Pharma [Seeking Alpha]
12/15
12:11 am
asnd
Assessing Ascendis Pharma (ASND)'s Valuation After a Strong 69.72% One-Year Shareholder Return [Yahoo! Finance]
Medium
Report
Assessing Ascendis Pharma (ASND)'s Valuation After a Strong 69.72% One-Year Shareholder Return [Yahoo! Finance]
12/12
03:25 pm
asnd
Ascendis Pharma gains amid takeover speculation [Seeking Alpha]
Low
Report
Ascendis Pharma gains amid takeover speculation [Seeking Alpha]
12/11
08:44 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Stifel Nicolaus from $254.00 to $256.00. They now have a "buy" rating on the stock.
Medium
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Stifel Nicolaus from $254.00 to $256.00. They now have a "buy" rating on the stock.